FDA Aims To Bolster Oversight Of Drug Safety Data

Law360, New York (January 18, 2008, 12:00 AM EST) -- The U.S. Food and Drug Administration is set to hold a public workshop to examine methods of collecting and reporting data about drugs’ side effects in a bid to address widespread criticism over its failure to recognize emerging drug safety issues in a timely manner.

The workshop, “Maximizing the Public Health Benefit of Adverse Event Collection Throughout a Product's Marketed Life Cycle,” is slated for Jan. 29.

It aims to solicit information on research approaches and methods associated with the best ways to assess the public...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.